uracil has been researched along with Menopause in 3 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
Menopause: The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A double blind study to compare the efficacy of oral UFT (400 mg Tegafur (FT) plus 896 mg uracil/day) with that of oral FT (800 mg/day) on advanced breast cancer was performed between November, 1986, and November, 1989." | 9.07 | A double blind comparative study of tegafur (FT) and UFT (a combination of Tegafur and uracil) in advanced breast cancer. ( Nomura, Y; Ohsaki, A; Tashiro, H, 1994) |
| "The elevation of serum iron level was noted in six out of 45 patients with breast cancers who were treated by medroxyprogesterone acetate (MPA) in Kinki University Hospital." | 7.68 | [The elevation of serum iron level with oral administration of medroxyprogesterone acetate (MPA) in patients with breast cancer]. ( Houjou, T; Kadota, K; Mori, N; Wada, T; Watatani, M; Yasutomi, M, 1991) |
| "Since June 1984, 23 cases of progressive or recurrent breast cancers were treated with combination chemotherapy of VAM-UFT consisting of vincristine, adriamycin, mitomycin C and UFT." | 7.67 | [Vincristine, adriamycin, mitomycin-C and UFT (VAM-UFT) therapy in progressive or recurrent breast cancer]. ( Hozumi, T; Imamura, Y; Irie, K; Katou, J; Matsushita, K; Okutani, T; Oya, M; Yasutake, K; Yoshimura, Y, 1989) |
| "A double blind study to compare the efficacy of oral UFT (400 mg Tegafur (FT) plus 896 mg uracil/day) with that of oral FT (800 mg/day) on advanced breast cancer was performed between November, 1986, and November, 1989." | 5.07 | A double blind comparative study of tegafur (FT) and UFT (a combination of Tegafur and uracil) in advanced breast cancer. ( Nomura, Y; Ohsaki, A; Tashiro, H, 1994) |
| "The elevation of serum iron level was noted in six out of 45 patients with breast cancers who were treated by medroxyprogesterone acetate (MPA) in Kinki University Hospital." | 3.68 | [The elevation of serum iron level with oral administration of medroxyprogesterone acetate (MPA) in patients with breast cancer]. ( Houjou, T; Kadota, K; Mori, N; Wada, T; Watatani, M; Yasutomi, M, 1991) |
| "Since June 1984, 23 cases of progressive or recurrent breast cancers were treated with combination chemotherapy of VAM-UFT consisting of vincristine, adriamycin, mitomycin C and UFT." | 3.67 | [Vincristine, adriamycin, mitomycin-C and UFT (VAM-UFT) therapy in progressive or recurrent breast cancer]. ( Hozumi, T; Imamura, Y; Irie, K; Katou, J; Matsushita, K; Okutani, T; Oya, M; Yasutake, K; Yoshimura, Y, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tashiro, H | 1 |
| Nomura, Y | 1 |
| Ohsaki, A | 1 |
| Kadota, K | 1 |
| Wada, T | 1 |
| Watatani, M | 1 |
| Houjou, T | 1 |
| Mori, N | 1 |
| Yasutomi, M | 1 |
| Yasutake, K | 1 |
| Imamura, Y | 1 |
| Yoshimura, Y | 1 |
| Oya, M | 1 |
| Matsushita, K | 1 |
| Hozumi, T | 1 |
| Katou, J | 1 |
| Okutani, T | 1 |
| Irie, K | 1 |
1 trial available for uracil and Menopause
| Article | Year |
|---|---|
A double blind comparative study of tegafur (FT) and UFT (a combination of Tegafur and uracil) in advanced breast cancer.
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Meth | 1994 |
2 other studies available for uracil and Menopause
| Article | Year |
|---|---|
[The elevation of serum iron level with oral administration of medroxyprogesterone acetate (MPA) in patients with breast cancer].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Femal | 1991 |
[Vincristine, adriamycin, mitomycin-C and UFT (VAM-UFT) therapy in progressive or recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Adm | 1989 |